OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
Model 1 | Model 2 | Model 3 | ||||
NT-proBNP | 4.24 (3.37 to 5.33) | 3.56×10–35 | 4.38 (3.42 to 5.61) | 9.81×10–32 | 3.83 (2.93 to 5.02) | 1.71×10–22 |
PON3 | 0.65 (0.54 to 0.78) | 2.75×10–6 | 0.66 (0.55 to 0.80) | 1.16×10–5 | 0.68 (0.55 to 0.84) | 3.15×10–4 |
TNFR1 | 1.11 (0.90 to 1.35) | 0.324 | 0.95 (0.77 to 1.18) | 0.658 | 0.80 (0.63 to 1.00) | 0.050 |
IGFBP-7 | 1.49 (1.22 to 1.83) | 1.24×10–4 | 1.37 (1.11 to 1.68) | 0.003 | 1.21 (0.96 to 1.51) | 0.102 |
FABP4 | 1.51 (1.23 to 1.86) | 8.73×10–5 | 1.49 (1.19 to 1.87) | 0.001 | 1.17 (0.90 to 1.53) | 0.247 |
OPN | 1.38 (1.11 to 1.71) | 0.004 | 1.23 (0.99 to 1.54) | 0.065 | 1.13 (0.90 to 1.43) | 0.300 |
MMP-2 | 1.33 (1.07 to 1.66) | 0.011 | 1.20 (0.96 to 1.50) | 0.110 | 1.10 (0.87 to 1.40) | 0.420 |
GAL-4 | 1.38 (1.11 to 1.71) | 0.003 | 1.23 (0.98 to 1.53) | 0.068 | 0.95 (0.74 to 1.21) | 0.661 |
UPAR | 1.30 (1.05 to 1.60) | 0.014 | 1.13 (0.91 to 1.41) | 0.267 | 0.95 (0.75 to 1.21) | 0.672 |
GDF-15 | 1.51 (1.24 to 1.85) | 4.73×10–5 | 1.27 (1.02 to 1.58) | 0.033 | 1.03 (0.80 to 1.33) | 0.813 |
CHI3L1 | 1.21 (0.99 to 1.48) | 0.066 | 1.07 (0.87 to 1.33) | 0.505 | 0.99 (0.79 to 1.24) | 0.931 |
Values are ORs and 95% CI for prevalent atrial fibrillation. Model 1 is unadjusted. Model 2 is age and sex adjusted. Model 3 is further adjusted for body mass index, systolic blood pressure, smoking status, prevalent diabetes mellitus, prevalent coronary events, prevalent heart failure and antihypertensive treatment.
CHI3L1, chitinase-3-like protein 1; FABP4, fatty-acid binding protein 4; GAL-4, galectin 4; GDF-15, growth differentiation factor 15; IGFBP-7, insulin-like growth factor-binding protein 7; MMP-2, matrix metalloproteinase-2; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OPN, osteopontin; PON3, paraoxonase 3; TNFR1, tumour necrosis factor receptor 1; UPAR, urokinase receptor.